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Abstract
PABPC1 (cytosolic poly(A)-binding protein 1) is an RNA-binding protein that binds to the poly(A) tail of mRNAs to promote
translation and mRNA turnover. In addition to RNA-binding domains, PABPC1 contains a unique protein-protein interaction
domain, MLLE (also known as PABC) that binds regulatory proteins and translation factors that contain a conserved 12
amino acid peptide motif termed PAM2. Eukaryotic Release Factor 3 (eRF3/GSPT1) contains two overlapping PAM2
sequences, which are required for its activity. Here, we determined the crystal structures of the MLLE domain from PABPC1
in complex with the two PAM2 regions of eRF3. The structures reveal a mechanism of cooperativity between the two PAM2
sites that increases the binding affinity but prevents the binding of more than one molecule of eRF3 to PABPC1. Relative to
previous structures, the high-resolution crystal structures force a re-evaluation of the PAM2 motif and improve our
understanding of the molecular basis of MLLE peptide recognition.
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Introduction
In order to rapidly respond to growth and proliferation stimuli,
stress, and nutrient availability, cells use translational control as an
important mechanism of gene expression. Cytoplasmic poly(A)-
binding protein (PABP), also termed PABPC or PABPC1, is an
essential protein that binds to and mediates the stimulatory effect
of the poly(A) tail on translation initiation [1]. PABPC1 contains
four N-terminal phylogenetically conserved RNA recognition
motifs (RRMs) while the proline-rich, C-terminal third of the
protein contains an unstructured, poorly conserved region, which
harbors some protein-interaction sites [2,3,4,5,6], and a well-
conserved, approximately 70-residue MLLE (Mademoiselle) domain,
also known as PABC [7]. The MLLE domain is also found in
UBR5 (or EDD), a ubiquitin-ligase [8].
Solution and crystal structures of MLLE domains from various
PABPs and human UBR5 have shown that these domains consist
of a bundle of 4 or 5 a-helices [7,8,9,10,11]. Previous studies
showed that MLLE is a peptide-binding domain that specifically
recognizes a conserved PAM2 (for PABP-interacting motif 2)
sequence [12]. This PAM2 motif was initially identified in Paip1
(PABP-interacting protein 1), Paip2 and eukaryotic Release Factor
3 (eRF3) [7]. Recent crystal structures of the MLLE domain from
human PABPC1 in complex with peptides from Paip2 and Ataxin-
2 reveal how the most conserved elements of PAM2 motifs bind to
the helices a2, a3 and a5 of MLLE but do not reveal the full range
of intermolecular interactions [13,14].
Eukaryotic release factor eRF3, also known as G1 to S phase
transition protein GSPT, is a GTPase that facilitates the nascent
peptidechainreleasefromtheterminatingribosome[15,16,17,18,19].
Two genes are known: eRF3a/GSPT1 and eRF3b/GSPT2 [20].
Structurally, both consists of a C-terminal GTPase domain,
homologous to elongation factor EF1A, and an N-terminal region
that contains the binding site for PABPC1 [21,22,23]. Unlike other
PAM2-containing proteins, eRF3 possesses two overlapping
PAM2 sequences (PAM2-N and PAM2-C), which each indepen-
dently bind to the MLLE domain of PABPC1 with low
micromolar affinity [12]. This makes them the most unusual
PAM2 motifs in the family. The C-terminal site (PAM2-C), in
particular, lacks a leucine recognition element that is found in
essentially all other PAM2 peptides. As a pair, the two PAM2 sites
bind to MLLE together with enhanced affinity and are responsible
for essentially all of the free energy of binding between the intact
proteins, eRF3 and PABPC1 [24].
Here, we determined two crystal structures of the MLLE
domain of human PABPC1 in complex with the PAM2-N and
PAM2-C peptides from human eRF3. The structures reveal a
shared binding element, Phe76, that contributes to binding as part
of both PAM2-N and PAM-C. The commonality between the two
binding sites explains the observations that the apparent loss of a
single PAM2 motif is sufficient to block eRF3 binding to PABPC1
[24,25]. Compared to previous low resolution NMR studies, the
high-resolution crystal structures reveal an enlarged lexicon of
peptide recognition by the MLLE domain of PABPC1 and
provide an example of binding site duplication as a means of
enhancing affinity.
Results
Structure of the MLLE/eRF3-PAM2 complexes
In order to understand eRF3 binding by PABPC1, we
crystallized the PABPC1 MLLE domain in complex with two
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10169peptides from the N-terminal portion of eRF3 that had previously
been shown to mediate PABPC1 binding. We obtained well-
diffracting co-crystals with eRF3 residues 67–81 (PAM2-N) and
76–90 (PAM2-C). Both crystals displayed very low solvent content
resulting from tight packing. Diffraction datasets for both
complexes were solved by molecular replacement and refined to
2.3 A ˚ for PAM2-N and 1.4 A ˚ for PAM2-C (Table 1; PDB codes
3KUI and 3KUJ).
Overlay of the MLLE/PAM2-N and MLLE/PAM2-C struc-
tures reveals striking similarity of the bound conformations despite
the highly divergent peptide sequences (Fig. 1). In both structures,
the peptide binds by wrapping around the highly conserved
KITGMLLE signature motif of MLLE and interacting with the
hydrophobic pockets between helices a2 and a3 and between
helices a3 and a5 of MLLE. The peptides adopt an extended
conformation interrupted by a b-turn at residues Asn70-Val71-
Asn72 in PAM2-N and at residues Asn79-Val80-His81 in PAM2-
C (Fig. 2).
The MLLE/PAM2 interactions are mostly hydrophobic with as
many as five conserved recognition elements. In the N-terminal
part of the peptide, the side chain of eRF3 Leu69 of PAM2-N
inserts into a hydrophobic pocket formed by the side chains of
Met584, Ile588, Ala610 and the aliphatic parts of Lys606 and
Glu609 (Fig. 2B). This same pocket is occupied by Phe76 and
Pro78 in the PAM2-C structure (Fig. 2 E). At the tip of the peptide
b-turn, the side chain of Val71/Val80 makes an additional
hydrophobic contact with the MLLE side chains of Val613 and
His617. Another hydrophobic interaction involves the invariantly
conserved alanine at residue 73 of PAM2-N and at 82 of PAM2-C.
At the C-terminus of both peptides, Phe76/Phe85 fits into the
shallow cavity formed by Gly563, the methyl groups of Thr582
and Leu586 and the aliphatic part of Glu564 (Fig. 2C, 2F).
Mutagenesis studies with Paip2 have shown that this is the single
most important determinant of binding [12]. In addition to its
essential side chain, the amide of Phe76/Phe85 hydrogen bonds
with the carbonyl of Gly579. This close approach of the two
backbones is reflected in the perfect conservation of this glycine in
the KITGMLLE motif.
The most significant differences between the two peptide
complexes occur at the N-terminus where PAM2-C lacks a highly
conserved leucine residue. Mutagenesis of this residue in the
PAM2 motif of Paip2 led to a loss of three orders of magnitude of
binding affinity [12]. In its place, Phe76 bends back to partly
occupy the space vacated by the missing leucine side chain. Thus
eRF3 Phe76 plays two distinct roles in the complexes, alternately
occupying the hydrophobic pocket between MLLE helices a2 and
a3 in the PAM2-N complex and between helices a3 and a5 in the
PAM2-C complex (Fig. 1B). The simultaneous requirement for
Phe76 for MLLE binding by both PAM2-N and PAM2-C explains
the previous observations of a one-to-one stoichiometry of eRF3
binding to PABPC1 despite the existence of two PAM2 motifs
[24,26].
Sequence conservation in PAM2 motifs
The high resolution structures of the peptides bound to the
PABPC1 MLLE domain allows a re-evaluation of the definition of
the PAM2 motif and the residues that are most essential for binding
[13,14]. We had previously described the motif as comprising 12
residues with a highly conserved leucine residue at position 3,
alanine at position 7 and phenylalanine at position 10 [7,12]. In
light of the eRF3 structures,the refined definition is--W-(P/V)-A--F-
P, where W, at position 3, is a hydrophobic residue, usually leucine
but occasionally proline or phenylalanine (Fig. 1A). Positions 1 and
2 are normally occupied by polar or charged residues, which do not
participate in MLLE binding except in the MLLE/PAM2-C
structure where phenylalanine in position 1 binds in combination
with proline at position 3. Position 4 is a polar residue, usually
asparagine or less often serine, whose side chain makes an
intermolecular ionic contact with Glu587 (the ‘‘E’’ in MLLE) and
also stabilizes the b-turn via a hydrogen bond with the amide of
residue at position 6 (Fig. 2B and 2E). The side chain of proline,
valine or occasionally threonine in position 5 fits snugly into a small
hydrophobic cavity in helix a5 of MLLE. The common occurrence
of proline in this position may due to its propensity to form b-turns.
Its mutagenesis to alanine decreased the affinity of the PAM2 motif
of Paip2 by 5-fold [12]. While positions 6 and 8 are solvent-exposed
and do not to contribute to MLLE binding, position 7 is invariantly
alanine and binds to the methionine of the MLLE signature motif.
Glutamic acid is preferred at position 9 and makes hydrogen bonds
with amides of Gly579 and Lys580 in the PAM2-C structure via
ordered water molecules (Fig. 2F). As previously noted, position 10
is invariantly phenylalanine and the single most important residue
forbinding.Whileposition11isnotconserved,position12isusually
occupied by proline, which makes an addition contact with MLLE
domain (Fig. 2C and 2E). While there is no sequence conservation
beyond position 12, the MLLE-binding region extends by at least
one more residue, as the backbone amide at position 13 makes a
Table 1. Data collection and refinement statistics.
MLLE-eRF3 (67–81) MLLE-eRF3 (76–90)
Data collection
Space group P21212P 2 1212
Cell dimensions
a, b, c (A ˚) 37.43, 63.63, 32.23 45.22, 50.80, 32.12
Resolution (A ˚) 50-2.30 (2.34-2.30)
1 50-1.40 (1.45-1.40)
Rsym 0.094 (0.415) 0.074 (0.375)
,I/sI. 19.3 (3.8) 19.2 (6.1)
Completeness (%) 99.7 (98.8) 99.6 (99.9)
Redundancy 7.0 (5.8) 7.5 (6.6)
Wilson B-factor (A ˚2) 47.4 14.7
Refinement
Resolution (A ˚) 50.0-2.30 33.77-1.40











Bond lengths (A ˚) 0.007 0.008
Bond angles (u) 1.15 1.25
Ramachandran statistics (%)
Most favored regions 96.2 97.4
Additional allowed regions 3.8 2.6
1Highest resolution shell is shown in parentheses.
doi:10.1371/journal.pone.0010169.t001
MLLE-eRF3 PAM2 Structure
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Interestingly, most intermolecular polar contacts involve the
backbone of the PAM2 peptide and do not directly affect side
chain specificity.
Discussion
eRF3 is the only known protein with two high affinity PAM2 sites
and the only example of overlapping sites. What is the function of
the juxtaposed sites? Previous studies showed that peptides
containing the individual PAM2 sites display moderate binding
affinities (Kd of 3.9 and 3.1 mM) while the peptide containing the
overlapping site shows a three-fold increase in binding affinity
(1.3 mM) [12]. This is 1.3 times higher than the value calculated for
twoindependentsites,basedonthelawofmassaction,andreflectsa
small degree of cooperativity between the sites. In agreement with
this, NMR titrations showed a large amount of conformational
exchange occurs between the two sites, presumably as the MLLE
domain slides along the eRF3 peptide binding alternately to PAM2-
N and PAM2-C [12]. One important distinction is that the eRF3-
PABPC1 complex exists exclusively in one-to-one stoichiometry as
Phe76 binding is essential for both complexes (Fig. 1B). Thus the
addition of a second, overlapping PAM2 site acts to augment the
affinity of the eRF3-PABPC1 interaction without changing the
stoichiometry of the interaction. The second site also provides
redundancy and reduces the frequency of loss of binding due to a
mutation in one of the PAM2 sites.
Intriguingly, this redundancy and higher affinity is lost in a
fraction of eRF3 in cells that is proteolytically cleaved in the
middle of PAM2-N site leaving Ala73 as the N-terminal residue
[27]. This cleavage product retains an intact PAM2-C site and,
based on our crystal structure and previous peptide affinity
measurements, would be expected to interact with PABPC1 with
3-fold lower affinity. The protease responsible for the cleavage of
eRF3 is not known but the cleavage is thought to be a regulatory
mechanism to regulate eRF3 levels/localization and potentiates
apoptosis by liberating caspases from inhibitors of apoptosis (IAPs)
that bind to the cleaved form of eRF3.
Figure 1. Overlapping PAM2 motifs of eRF3. (A) Sequence of MLLE-binding PAM2 motifs. PAM2-N and PAM2-C of eRF3 are aligned against
sequences from Tob (transducer of Erb1), poly(A) specific ribonuclease 3 (PAN3), PABP-interacting protein 2 (Paip2) and Ataxin-2. Residues in the
overlap are underlined. The consensus of most conserved residues that contribute to the MLLE/PAM2 binding is shown: W represents a hydrophobic
residue [12]. (B) Overlaid structures of the complexes of eRF3 PAM2-N (yellow) and PAM2-C (magenta) bound to the MLLE domain (grey) from
PABPC1. eRF3 Phe76 shifts position and binds to either MLLE helix a2/a3 in the PAM2-N complex or helix a3/a5 in the PAM2-C complex. Leu69 or
Phe85 then occupies the vacated hydrophobic binding site. (C) Stick representation of overlaid structures of eRF3 PAM2-N (yellow) and PAM2-C
(magenta) bound to the MLLE domain from PABPC1 (green).
doi:10.1371/journal.pone.0010169.g001
MLLE-eRF3 PAM2 Structure
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regulating mRNA deadenylation [26]. Through the MLLE
domain, PABPC1 interacts with two mRNA deadenylation
systems, PAN2-PAN3 and Ccr4-Not-Caf1, and contributes to
deadenylation of cytosolic mRNAs (Fig. 3). In both systems,
binding occurs through a linker protein, PAN3 or Tob, that
contains a PAM2 motif [28,29,30,31]. These deadenylase
complexes compete with eRF3 for binding to the MLLE domain
so that their recruitment to the mRNA is regulated by eRF3 [26].
Peptide binding studies show that the overlapped PAM2 motifs of
eRF3 binding with significantly (up to 30 fold) higher affinity than
the PAM2 motifs of PAN3 and Tob [12,28,32]. Comparison of the
PAM2 motifs of PAN3 and eRF3 highlights the importance of the
N-terminal residues (Fig. 1A). While PAN3 does have a proline
residue at position 3, it lacks the phenylalanine residue at position
1 that binds to the MLLE hydrophobic pocket between helices a3
and a5.
Binding studies with the full-length proteins PABPC1 and eRF3
have reported affinities very similar to those measured for MLLE
binding the overlapping PAM2 site [24]. Thus, it appears that the
PAM2 motifs of eRF3 are the only interaction sites for binding to
PABPC1. This is supported by mutagenesis studies. Recently, a
four residue mutant of eRF3 (L69K, N72A, A73K, F76A) was
shown to have a compromised binding to PABPC1 [25]. Similarly,
mutagenesis of the PAM2-C sequence (H81A, A82K, F85A) was
shown to block eRF3 binding to PABPC1 as measured by
isothermal titration calorimetry [24]. These are consistent with
studies of other PAM2-containing proteins, which have shown that
the phenylalanine residue at position 10 is required for binding
and function. Specifically, mutagenesis of PAN3 (F93A) [28], Tob
(F274A) [26] and NFX1-123 (F20A) [33] were all shown to disrupt
binding to PABPC1 in cells.
In summary, the high-resolution X-ray crystal structures
presented here significantly improve our understanding of the
eRF3-PABPC1 interactions and, in general, PAM2 recognition by
the MLLE domain of PABPC1. Despite significant sequence
divergence, the two PAM2 peptides of eRF3 bind with almost
identical conformations and show synergy when combined as an
overlapped pair of binding sites. The refined definition of the
PAM2 motif strongly suggests that other more divergent PAM2-
containing proteins, such as PAN3 and Tob, will interact with
PABPC1 in a manner very similar to the eRF3 PAM2 motifs.
Figure 2. Crystal structures of the MLLE/eRF3-PAM2 complexes. (A) Cartoon representation of the MLLE domain (green) with eRF3 PAM2-N
(yellow). (B) Details of the eRF3 PAM2-N structure. The eRF3 peptide makes a b-turn stabilized by hydrogen bonds between carbonyl of Asn70 and
amide of Ala73 and between side chain of Asn70 and amide of Asn72. Mlle binding is mediated by several hydrophobic interactions: Leu69 binding
to the pocket formed by Leu585, Ala610, and the aliphatic portion of Lys606 of MLLE, Val71 inserting into a smaller pocket formed by the side chains
of Met584, Val613, Leu614 and His617, and Ala73 contacting the Met584 side chain. Intermolecular hydrogen bonds occur between the side chain of
MLLE Lys580 with carbonyls of Val71 and Ala73 of Paip2. (C) C-terminal portion of PAM2-N. Phe76 binds the shallow pocket formed by Thr582,
Phe567, Leu586 and Gly563 of MLLE. The amide of this phenylalanine is engaged in hydrogen bonding with carbonyl of MLLE Gly579. Pro78 of eRF3
interacts with the aromatic ring of Phe567. Side chains of Gln560 and Glu564 of MLLE form a network of intermolecular hydrogen bonds with the
amides of Val77 and Asn79 of eRF3. (D) Cartoon representation of the MLLE domain (green) with eRF3 PAM2-C (magenta). (E) Details of the eRF3
PAM2-C structure. The aromatic side chain of eRF3 Phe76 binds in the hydrophobic cavity previously occupied by Leu69 of the PAM2-N peptide,
while Pro78 interacts with the side chain of Val617. Side chain of Asn79 also makes a salt bridge with MLLE Glu587. (F) C-terminal portion of PAM2-C.
The interactions of eRF3 Phe85 and Pro87 with MLLE are identical to those of Phe76 and Pro78 in the PAM2-N structure. The side chain of Glu84 of
eRF3 forms intermolecular hydrogen bonds with amides of Gly579 and Lys580 via an ordered water molecule. Hydrogen bonds are shown in black,
ordered water molecules in cyan. Figures were made with PyMOL (http://pymol.sourceforge.net/).
doi:10.1371/journal.pone.0010169.g002
MLLE-eRF3 PAM2 Structure
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MLLE expression, purification and peptide synthesis
The MLLE domain (residues 544–626) of human PABPC1 was
cloned into pGEX-6P-1 vector (Amersham-Pharmacia) and
expressed and purified as described previously for the longer
544–636 fragment [12] with the addition of a final size-exclusion
chromatography step.
The PAM2 peptides were synthesized by Fmoc solid-phase
peptide synthesis and purified by reverse phase chromatography
on a C18 column (Vydac, Hesperia, CA). The composition and
purity of the peptides was verified by ion-spray quadruple mass
spectroscopy.
Crystallization
Crystallization conditions for the MLLE domain in complex with
the PAM2 peptides from eRF3 were identified utilizing hanging drop
vapor diffusion with the AmSO4 crystallization suite (QIAGEN). The
best MLLE/PAM2-N crystals were obtained by equilibrating a 1 ml
drop of PABPC1 (544–626)/eRF3 (67–81) mixture (10 mg/ml) in 1:2
molar ratio in a buffer (10 mM MES, 100 mM NaCl, pH 6.3),
mixed with 1 ml of reservoir solution containing 2.1 M ammonium
sulfate, 0.2 M sodium sulfate, 10 mM zinc chloride and 0.1 M
sodium acetate at pH 5.4. Crystals grew in 10–20 days at 22uC. The
solution for cryoprotection contained the reservoir solution with the
addition of 15% (v/v) glycerol. The crystals contain one MLLE and
one PAM2-N molecule in the asymmetric unit corresponding to
Vm=1.7 A ˚ 3 Da
21 and a solvent content of 28.5%. The bestMLLE/
PAM2-C crystals were obtained by equilibrating a 1 mld r o po f
PABPC1 (544–626)/eRF3 (76–90) mixture (10 mg/ml) in 1:2 molar
ratio in a buffer (10 mM MES, 100 mM NaCl, pH 6.3), mixed with
1 ml of reservoir solution containing 1.4 M ammonium sulfate and
0.1 M citric acid pH 4.0. Crystals grew in 5–10 days at 22uC. The
solution for cryoprotection contained the reservoir solution with the
addition of 20% (v/v) glycerol. The crystals contain one MLLE and
one PAM2-C molecule in the asymmetric unit corresponding to
Vm=1.7 A ˚ 3 Da
21 and a solvent content of 26.1% [34].
Structure solution and refinement
Diffraction data from a single crystal of the MLLE/PAM2-C
complex were collected on an ADSC Quantum-210 CCD
detector (Area Detector Systems Corp.) at beamline F2 at the
Cornell High-Energy Synchrotron Source (CHESS) (Table 1).
Diffraction data from a single crystal of the MLLE/PAM2-N
complex were collected on a Rigaku R-Axis IV++ imaging-plate
detector at the McGill Macromolecular X-ray Diffraction Facility.
Data processing and scaling were performed with HKL2000 [35].
The structures were determined by molecular replacement with
Phaser [36], using the coordinates of unliganded MLLE from
human EDD (PDB entry 1I2T). The initial MLLE/PAM2-C
model obtained from Phaser was completed and adjusted with the
program Coot [37] and improved by several cycles of refinement,
using the program REFMAC 5.2 [38] and model refitting. At the
latest stage of refinement, we also applied the translation-libration-
screw (TLS) option [39] with final density for PABPC1 residues
544–620 and eRF3 residues 76–90. The MLLE/PAM2-N model
was refined using CNS [40] with density for PABPC1 residues
545–625 and eRF3 residues 67–80. The models have good
stereochemistry according to the program PROCHECK [41]
(Table 1) and well-defined density for the bound peptide
(Supplemental Figure S1).
Supporting Information
Figure S1 Electron density from the eRF3 PAM2-N (A) and
PAM2-C (B) peptides contoured at 1 s from the 2FO-FC omit
maps. The PAM2-N (yellow) and PAM2-C (magenta) peptides are
shown in stick representation and the MLLE domain is shown in
cartoon representation (green).
Found at: doi:10.1371/journal.pone.0010169.s001 (0.15 MB
PDF)
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